貨號(hào)：GS40026

Anetumab is an investigational, fully human monoclonal antibody (IgG1) that targets the tumor-associated antigen mesothelin. It is developed as an antibody-drug conjugate (ADC), where the antibody is linked to the potent cytotoxic agent tubulysin B. The construct is designed to specifically deliver the toxin to mesothelin-expressing cancer cells, where it is internalized and releases the payload, leading to targeted cell death. It has been primarily investigated in clinical trials for the treatment of mesothelioma, ovarian cancer, and pancreatic cancer, representing a strategy to exploit mesothelin overexpression for targeted chemotherapy delivery.